Press Releases

Press Releases

View all news
Voronoi Successfully Transfers VRN04 Program... Signs Definitive Purchase Agreement
2025.09.19
Voronoi disclosed on the 18th that it has signed a technology (asset) purchase agreement for the follow-on development rights to VRN04, its oral anti-inflammatory therapy, with Anvia Therapeutics ("Anvia"), a U.S.-based biotech.

Voronoi initially received 2.5 million shares of Anvia common stock in August of last year under an option agreement for research on the VRN04 program, and with the signing of this purchase agreement following the exercise of the option, it has received 3 million shares of Anvia common stock as an upfront payment.

VRN04 is expected to have an anti-inflammatory effect by inhibiting RIPK1, which mediates TNF-α receptor signaling, a target that global pharmaceutical companies such as Eli Lilly and Sanofi are also developing.

Daekwon Kim, CEO of R&D at Voronoi, commented, "Since signing the option agreement with Anvia in August 2024, we are pleased to have been able to derive a compound that satisfies all of the technical requirements our partner needed. Many of Anvia's executives come from global pharmaceutical companies such as Genentech and GSK. Having been able to meet their demanding requirements is proof that Voronoi's drug design technology has secured global competitiveness."